VTVT
vTv Therapeutics Inc.35.14
+1.38+4.09%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
138.38MP/E (TTM)
-Basic EPS (TTM)
-3.30Dividend Yield
0%Recent Filings
8-K
8-K
10-Q
Q3 FY2025 results
vTv Therapeutics posted Q3 operating loss of $10.7M, up 64% y/y from $6.5M (derived), driven by cadisegliatin spend jumping to $4.0M from $1.5M amid clinical studies and a $1.0M Novo Nordisk milestone accrual; nine-month loss hit $24.9M, 29% worse y/y (derived), with no revenue after 2024's $1M Newsoara milestone. Diluted EPS of $(1.08) aligns with 8.1M weighted shares. Cash swelled to $98.5M on $77.5M net from August private placement of 5.2M units (682K shares, pre-funded warrants, common warrants). Cash burn eased to $16.0M YTD from $20.5M. Equity financings fuel runway. Clinical holds pose delays.
8-K
Secures $80M for Phase 3 trial
vTv Therapeutics bolstered its balance sheet with an $80 million private placement closed in September 2025, lifting cash to $98.5 million from $36.7 million year-end 2024. First patient randomized in August for Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes; topline data eyed H2 2026. New U.S. patent extends exclusivity to 2041. Funds secure trial completion.
ALT
Altimmune, Inc.
5.03-0.25
APLT
Applied Therapeutics, Inc.
0.12+0.00
DMAC
DiaMedica Therapeutics Inc.
8.76+0.09
IVA
Inventiva S.A. - American Depos
4.66+0.18
MTVA
MetaVia Inc.
8.14-0.17
TVRD
Tvardi Therapeutics, Inc.
4.20-0.02
VKTX
Viking Therapeutics, Inc.
35.72-0.43
VNDA
Vanda Pharmaceuticals Inc.
6.65+0.02
ZVRA
Zevra Therapeutics, Inc.
8.12-0.05
ZVSA
ZyVersa Therapeutics, Inc.
0.13-0.00